Emergency use is allowed for the treatment of COVID-19 in adults and adolescents over 12 years of age.
The US Food and Drug Administration (FDA) has approved the emergency use of the drug for the treatment of COVID-19 Sotrovimab (VIR-7831) by the British pharmaceutical company GSK (GlaxoSmithKline) and its American partner Vir Biotechnology. This is stated in a statement published on the website of the pharmaceutical regulator.
It is noted that the drug is approved for the treatment of COVID-19 (a disease caused by a new coronavirus), which occurs in mild to moderate form, in adult patients and adolescents aged 12 years and older, whose weight exceeds 40 kg. The use of Sotrovimab is prohibited for patients who are hospitalized with COVID or require oxygen therapy.
VIR-7831 is a drug based on a single type of monoclonal antibody-cloned molecules produced by the immune system and able to bind and neutralize the causative agent of a certain disease. In March, the developers of the drug reported that patients with COVID are well tolerated by the therapy. Clinical trials will continue and patients will be monitored for 24 weeks. GSK and Vir are also testing another monoclonal antibody, VIR-7832, which should activate T-cell immunity in COVID-19.